Domov › Množni mielom › Texas › Houston
Klinične študije za Množni mielom v Houston, TX
38 študij za Množni mielom išče udeležence na lokacijah v Houston in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.
Uradno besedilo študije (angleško)
Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Vključevanje udeležencevFaza 3
- Research Site, Houston
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
Vključevanje udeležencevFaza 1
- MD Anderson Cancer Center, Houston
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
Vključevanje udeležencevFaza 1
- Research Site, Houston
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Vključevanje udeležencevFaza 3
- MD Anderson Cancer Center, Houston
A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
Vključevanje udeležencevFaza 1/2
- MD Anderson, Houston
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Vključevanje udeležencevFaza 3
- Houston Methodist Hospital, Houston
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Vključevanje udeležencevFaza 3
- The University of Texas MD Anderson Cancer Center, Houston
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Vključevanje udeležencevFaza 4
- MD Anderson Cancer Center, Houston
A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
Vključevanje udeležencevFaza 1
- Oncology Consultants (P1 Trials -Exigent Network), Houston
- Lumi Research, Houston
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Vključevanje udeležencevFaza 2
- The University of Texas MD Anderson Cancer Center, Houston
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Vključevanje udeležencevFaza 3
- The University of Texas MD Anderson Cancer Center, Houston
A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"
Vključevanje udeležencevFaza 2
- MD Anderson Cancer Center, Houston
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
Vključevanje udeležencevFaza 1/2
- MD Anderson Cancer Center, Houston
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Vključevanje udeležencevFaza 3
- University of Texas MD Anderson Cancer Center, Houston
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Vključevanje udeležencevFaza 2
- University of Texas MD Anderson Cancer Center, Houston
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
Vključevanje udeležencevFaza 1/2
- University of Texas MD Anderson Cancer Center, Houston
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
Vključevanje udeležencevFaza 1/2
- Research Site, Houston
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Vključevanje udeležencevFaza 3
- Houston Methodist Cancer Center Infusion, Houston
- Houston Methodist Hospital - Department of Pharmacy, Houston
- Houston Methodist Hospital Cancer Center, Houston
- in še 3
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
Vključevanje udeležencevFaza 1/2
- MD Anderson Cancer Center, Houston
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Vključevanje udeležencevFaza 1/2
- Research Site, Houston
Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma
Vključevanje udeležencevFaza 2Vabljeni zdravi prostovoljci
- MD Anderson Cancer Center, Houston
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Vključevanje udeležencevFaza 3
- Research Site, Houston
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
Vključevanje udeležencevFaza 1
- Houston Methodist Hospital, Houston
Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma
Vključevanje udeležencevFaza 1/2
- M D Anderson Cancer Center, Houston
Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma
Vključevanje udeležencevFaza 2
- MD Anderson Cancer Center, Houston
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
Vključevanje udeležencevFaza 1/2
- M D Anderson Cancer Center, Houston
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Vključevanje udeležencevFaza 1
- University of Texas MD Anderson Cancer Center, Houston
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Vključevanje udeležencevFaza 1
- Oncology Consultants /ID# 268323, Houston
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Vključevanje udeležencevFaza 3
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
- M D Anderson Cancer Center, Houston
- in še 2
Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients
Vključevanje udeležencevFaza 2
- M D Anderson Cancer Center, Houston
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Vključevanje udeležencevFaza 3
- Houston Methodist Hospital, Houston
Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies
Vključevanje udeležencevOpazovalna študija
- M D Anderson Cancer Center, Houston
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
Vključevanje udeležencevFaza 1/2
- The University of Texas MD Anderson Cancer Center, Houston
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Vključevanje udeležencevFaza 1
- MD Anderson Cancer Center, Houston
Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma
Vključevanje udeležencevFaza 2
- M D Anderson Cancer Center, Houston
ATRA and Carfilzomib in Plasma Cell Myeloma Patients
Vključevanje udeležencevFaza 1/2
- Houston Methodist Neal Cancer Center, Houston
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Vključevanje udeležencevFaza 1/2
- MDACC, Houston
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Vključevanje udeležencevFaza 1/2
- University of Texas MD Anderson Cancer Center, Houston
Študije za Množni mielom v drugih mestih
- New York City, NY60 študij
- Boston, MA42 študij
- Atlanta, GA41 študij
- Durham, NC37 študij
- Nashville, TN32 študij
- Denver, CO27 študij
- Rochester, MN24 študij
- St. Louis, MO24 študij
- Columbus, OH24 študij
- Baldwin Park, CA23 študij
- Chicago, IL22 študij
- Seattle, WA22 študij
Druge študije v Houston
- Nemalicelični pljučni rak145 študij
- Rak dojke126 študij
- Rak (vse vrste)121 študij
- Metastatski rak104 študij
- Kolorektalni rak102 študij
- Rak jajčnikov89 študij
- Akutna mieločna levkemija85 študij
- Rak pljuč78 študij
- Rak prostate76 študij
- Rak endometrija68 študij
- Rak trebušne slinavke61 študij
- Melanom59 študij
Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.